Related Experiment Video

Updated: Aug 18, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

[Development of farsenyl transferase inhibitors as anticancer agents]

Ph Cestac1, S Doisneau-Sixou, G Favre

  • 1Inserm U563, Département innovation thérapeutique et oncologie moléculaire, F31052 Toulouse, France.

Annales Pharmaceutiques Francaises
|April 2, 2005
PubMed

Insights

Farnesyl transferase inhibitors (FTIs) target Ras protein processing, crucial for cancer cell growth. Clinical trials show FTIs possess significant antitumor activity and low toxicity, positioning them as promising cancer therapeutics.

Area of Science:

  • Molecular Biology
  • Oncology
  • Biochemistry

Context:

  • Ras proteins, key regulators of cell signaling, are frequently mutated in human cancers.
  • Ras oncogenic activity depends on plasma membrane localization, mediated by farnesylation.
  • Farnesyl transferase inhibitors (FTIs) were developed to block Ras processing and tumor growth.

Purpose:

  • To investigate the therapeutic potential of Farnesyl transferase Inhibitors (FTIs) in cancer treatment.
  • To evaluate the efficacy and safety of FTIs in preclinical and clinical settings.
  • To determine the role of FTIs in targeting Ras-driven tumorigenesis.

Summary:

  • Ras proteins are monomeric GTPases controlling cell growth and survival; mutations drive tumorigenesis.
  • Protein farnesylation, catalyzed by farnesyl transferase, is essential for Ras membrane localization and oncogenic function.
  • FTIs inhibit Ras processing, showing preclinical efficacy against diverse cancer cell lines, including those with wild-type Ras.
  • Phase I/II clinical trials demonstrate significant antitumor activity and low toxicity for FTIs.
  • Ongoing Phase III trials will define FTIs' role in treating solid and hematologic tumors, potentially in combination therapies.

Impact:

  • FTIs exhibit broad-spectrum anticancer activity, impacting both mutated and wild-type Ras pathways.
  • Clinical development of FTIs shows promise for a new class of anticancer drugs.
  • FTIs may enhance conventional cancer therapies, offering new combination treatment strategies.

More Related Videos

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment10:33

Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment

Published on: April 25, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...